With stronger antiplatelet efficacy, novel P2Y12 antagonists, prasugrel and ticagrelor, have been widely used among patients with acute coronary syndrome or high thrombotic risk (4, 5). This evidence concerns the gene P2RY12 and acute coronary syndrome.